Michael Gladstone, partner at Atlas Venture

At­las rais­es new $400M fund amid spree of VC rais­es. Here’s what they’ll spend it on

You can add an­oth­er few hun­dred mil­lion to the now Mon­tana-sized reser­voir of cash biotech VCs have raised since the WHO de­clared Covid-19 a pan­dem­ic.

At­las Ven­ture, the promi­nent Kendall Square in­cu­ba­tor, has raised $400 mil­lion for its twelfth biotech fund, their first in 3 years. Af­ter a string of mam­moth new rais­es from oth­er ma­jor VCs in April and May, the to­tal pot now stands be­tween $5 bil­lion and $6 bil­lion, de­pend­ing on how you slice it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.